Pyxis Oncology, Inc. 8-K

What Happened
Pyxis Oncology, Inc. (PYXS) filed an 8-K reporting the results of its virtual Annual Meeting of Stockholders held June 15, 2026. As of the April 20, 2026 record date there were 62,855,464 shares outstanding; 47,302,035 shares were present (virtually, in person or by proxy), establishing a quorum. Stockholders elected three Class II directors — Thomas Civik, Dr. Freda Lewis‑Hall, M.D., and Michael A. Metzger — each to serve until the 2029 annual meeting, and they ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Record date and attendance: 62,855,464 shares outstanding (April 20, 2026); 47,302,035 shares present at the meeting.
• Director election votes:
  • Thomas Civik: For 27,341,415; Withheld 1,981,857; Broker non‑votes 17,978,763.
  • Dr. Freda Lewis‑Hall, M.D.: For 19,188,755; Withheld 10,134,517; Broker non‑votes 17,978,763.
  • Michael A. Metzger: For 26,521,575; Withheld 2,801,697; Broker non‑votes 17,978,763.
• Auditor ratification: Ernst & Young LLP ratified — For 46,203,257; Against 1,076,997; Abstain 21,781.

Why It Matters
The filing confirms the company’s board composition (three Class II directors re/appointed through 2029) and corporate governance matters were approved by shareholders. Vote totals show differing levels of shareholder support across the director nominees (notably higher withheld votes for Dr. Lewis‑Hall), and broker non‑votes were material to the director tallies because of the company’s multi-class voting context. Ratification of Ernst & Young LLP as auditor is a routine but important governance vote confirming the independent auditor for fiscal 2026. The 8-K was signed by Jitendra Wadhane, Principal Financial and Accounting Officer, on June 15, 2026.